Ariya Bio
Company Type: Therapeutics
Main focus: Development of genome editing therapies for haemoglobinopathies
Company stage: Pre-clinical
Diseases: Haemoglobinopathies
Genome-editing tool: CRISPR-Cas
Funding stage: Pre-seed
Location: Schlieren, Switzerland
Website: https://www.ariyabio.ch/
Pipeline:
Partners:
Ariya Bio is a pre-clinical stage company that focuses on developing new CRISPR-based cell and gene therapies for hereditary blood diseases. Their current programmes are focused on beta-haemoglobinopathies and alpha-thalassemia.